Covered in the latest feature of Pharmaphorum.
Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new seed funding activity.
“We believe that in the midst of every crisis lies great opportunity,” said Marc Cikes, managing director of Debiopharm Innovation Fund. “We see a new generation of innovators emerging, who are facing a tough market environment. By investing earlier at more reasonable valuations, we can serve as a stepping-stone to successful Series A funding for the most promising Seed start-ups in need of capital and strategic guidance.”
Discover the full article here